Marker Therapeutics, Inc. insider trading
Every open-market purchase and sale by Marker Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Does following Marker Therapeutics, Inc.’s insiders pay?
From April 5, 2011 to December 26, 2024, 10 insiders reported 11 open-market purchases and 1 sale not made under a pre-set plan in Marker Therapeutics, Inc. Twelve months after each purchase was reported, the shares were −84.9% against the S&P 500 on average (median −84.9%), over 1 purchase with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 16, 2019 into $4,202 by November 2, 2026, −11.4% a year. It held shares 14% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $14,568 (+5.4% a year), and held throughout $29,078 (+16.0%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Elms Steve | Director | 2 | — | — | 0 | — | December 26, 2024 |
| Hoang Peter L. | President and CEO | 2 | −84.9% (1) | 0% | 0 | — | March 18, 2021 |
| Corin Denis | President and CFO | 0 | — | — | 1 | — | April 5, 2011 |
| Dart Kenneth Bryan | 10% owner | 1 | — | — | 0 | — | May 16, 2018 |
| Eansor Norman David | Director | 1 | — | — | 0 | — | June 8, 2023 |
| Makower Joshua and related entities | 10% owner | 1 | — | — | 0 | — | March 18, 2021 |
| Nea Partners 16, L.P. | 10% owner | 1 | — | — | 0 | — | December 23, 2024 |
| Vera Juan | Chief Development Officer | 1 | — | — | 0 | — | March 18, 2021 |
| Wasserman Frederick Gerald | Director | 1 | — | — | 0 | — | May 20, 2021 |
| Wilson John Robert | Director | 1 | — | — | 0 | — | March 18, 2021 |